Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre

Nicoletta Ciccarelli, Roberto Cauda, Simona Di Giambenedetto, Alberto Borghetti, Annalisa Mondi, Roberta Gagliardini, Alessandro D'Avino, Federico Pallavicini, Andrea De Luca, Massimiliano Fabbiani, B Piccoli, S Lamonica

Research output: Contribution to journalConference articlepeer-review

Abstract

According to recent evidence about boosted protease inhibitors (PIs/r)-simplified regimens, the combination of 3TC and DRV/r 800/100 mg could represent a feasible option for optimizing antiretroviral therapy (ART) in treatment-experienced HIV+ patients.
Original languageEnglish
Pages (from-to)19817-19817
Number of pages1
JournalJournal of the International AIDS Society
Volume17
DOIs
Publication statusPublished - 2014
EventHIV Drug Therapy Glasgow Congress 2014 - Glasgow
Duration: 2 Nov 20146 Nov 2014

Keywords

  • HIV
  • therapy

Fingerprint

Dive into the research topics of 'Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre'. Together they form a unique fingerprint.

Cite this